Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Jun;14(2):136-143.
doi: 10.1177/19476035221109230. Epub 2022 Dec 17.

The Association between Radiographic Features and the Duration of Effectiveness of a Single Injection of Extended-Release Hyaluronic Acid (HANOX-M-XL) in Patients with Knee Osteoarthritis: Preliminary Results of a Prospective Trial

Solène Perruchet  1 , Jean-Charles Balblanc  2 , Charles Rapp  2 , Charlotte Bourgoin  3 , Cerise Guillochon  2 , Anne Lohse  2 , Thierry Conrozier  2   3
Affiliations
Clinical Trial

The Association between Radiographic Features and the Duration of Effectiveness of a Single Injection of Extended-Release Hyaluronic Acid (HANOX-M-XL) in Patients with Knee Osteoarthritis: Preliminary Results of a Prospective Trial

Solène Perruchet et al. Cartilage. 2023 Jun.

Abstract

Background: Advanced radiological stage of knee osteoarthritis (OA) is predictive of poor response to viscosupplementation (VS). To date, the impact of x-ray features on the duration of effectiveness (DE) of VS has not been investigated.

Objectives: To investigate the radiological features associated with DE of VS in patients with knee OA.

Methods: Cross-sectional study in patients with knee OA treated with 1 injection of cross-linked hyaluronic acid (HA). The primary outcome was DE, self-assessed by the patients in weeks of effectiveness. Radiological features (joint space narrowing-JSN topography and Kellgren-Lawrence [K-L] grade) associated with DE were studied.

Results: Fifty-one patients-33 females (76 knees)-were analyzed. The average DE was 52.0 (24.7) weeks (range, 13-155 weeks). In the bivariate analysis, DE was 14 weeks longer in those with K-L grades 1 and 2 (62.6 ± 36.4 weeks) than in those with K-L 3 and 4 (48.9 ± 18.6) (P = 0.03). DE was not significantly different according to the involved compartment(s). It was significantly longer in men than in women (60 ± 31.4 vs. 47 ± 16 weeks; P = 0.035). In multivariate analysis, K-L grade (1-2 vs. 3-4) (P = 0.007), male gender (0.02), and older age (0.04) were independently associated with a longer DE.

Conclusion: DE of a single injection of extended-release HA is longer in K-L 1-2 than in K-L 3-4 OA knees, regardless of the JSN topography. However, even the patients with more advanced OA benefited from HANOX-M-XL injection for an average duration barely less than 1 year.

Trial registration: ClinicalTrials.gov NCT04988698.

Keywords: HANOX-M-XL; Kellgren-Lawrence scale; cross-linking; effectiveness; hyaluronic acid; knee; osteoarthritis; viscosupplementation.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TC received fees from LABRHA, SANOFI, MEDAC, and FIDIA for scientific and board member services. CB, SP, CR, CG, J-CB: None; AL received fees from VIVACY for consultant services.

Figures

Figure 1.
Figure 1.
Duration of effectiveness (weeks) of 1 injection of HANOX-M-XL according to the Kellgren-Lawrence radiological grading scale (1-4).
Figure 2.
Figure 2.
Duration of effectiveness (weeks) of 1 injection of HANOX-M-XL according to the Kellgren-Lawrence radiological grading scale (1 + 2 vs. 3 + 4). K-L = Kellgren-Lawrence.
See this image and copyright information in PMC

References

    1. Jackson J, Iyer R, Mellor J, Wei W. The burden of pain associated with osteoarthritis in the hip or knee from the patient’s perspective: a multinational cross-sectional study. Adv Ther. 2020;37(9):3985-99. doi:10.1007/s12325-020-01445-4. - DOI - PMC - PubMed
    1. Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al.. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. doi:10.1016/j.semarthrit.2019.04.008. - DOI - PubMed
    1. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al.. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-55. - PMC - PubMed
    1. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al.. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. doi:10.1016/j.joca.2019.06.011. - DOI - PubMed
    1. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol. 1993;39:3-9. - PubMed

Publication types

Substances

Associated data